curriculum vitae (september 2, 2014) ssn:...
TRANSCRIPT
1
Curriculum Vitae (September 2, 2014) Name: Robert M. Jackson Date of Birth: August 27, 1952 SSN: Redacted Family: Redacted Research Interests: Oxidant stress as a mechanism in interstitial lung disease Hypoxic cellular physiology and metabolism Pulmonary oxygen toxicity/reoxygenation injury Alveolar epithelial cell biology Office Address:
Research Service VAHS (151) 1201 NW 16th Street Miami, FL 33125-1693 Tel 305-575-3548 Fax 305-575-3126 E-mail [email protected] or [email protected]
2
Secondary School: 1966-1970 Somerset High School, Somerset, Massachusetts College: 1973 A.B. Magna cum Laude Boston University (Combined 6-year program in liberal arts and medicine)
(See http://jama.ama-assn.org/content/235/24/2618.abstract)
Medical School: 1976 M.D., Boston University School of Medicine Internship:
1976-1977 University of Miami Affiliated Hospitals Straight Medicine
Residency:
1977-1979 University of Miami Affiliated Hospitals Internal Medicine
Fellowship:
1979-1980 University of Miami Affiliated Hospitals Pulmonary Fellowship
1980-1981 University of Miami School of Medicine
Pulmonary Research Fellowship, supported by NIH Training Fellowship HL 07283 and a Research Fellowship from the American Lung Association of Florida
1981-1983 Post-doctoral Research Associate
Institute for Environmental Medicine University of Pennsylvania School of Medicine
Appointments:
1983-2003 Staff Physician, Pulmonary Section Birmingham Veterans Administration Medical Center, Birmingham, Alabama
1983-1989 Assistant Professor of Medicine
3
Division of Pulmonary and Critical Care Medicine Department of Medicine and School of Medicine University of Alabama at Birmingham Birmingham, Alabama
1989-1998 Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine Department of Medicine University of Alabama at Birmingham Birmingham, Alabama
1991-1992 Visiting Associate Professor (sabbatical leave) Division of Allergy, Critical Care and Respiratory Medicine
Department of Medicine Duke University Durham, North Carolina
1996-2003 Associate Professor of Physiology and Biophysics
Department of Physiology and Biophysics University of Alabama at Birmingham Birmingham, Alabama
1998-2003 Professor of Medicine
Division of Pulmonary and Critical Care Medicine Department of Medicine University of Alabama at Birmingham Birmingham, Alabama
2000-2003 Associate Professor of Environmental Health Sciences University of Alabama at Birmingham Birmingham, Alabama
1999-2003 Director, UAB-HSF IPF Clinical Program University of Alabama at Birmingham and Kirklin Clinic Birmingham, Alabama
Current Appointments:
2003-pres. Associate Chief of Staff for Research and Development VAMC Miami, Florida 2004- pres. Professor of Medicine Division of Pulmonary and Critical Care Medicine University of Miami School of Medicine Miami, Florida
4
Professional Societies: American Thoracic Society
American Federation for Clinical Research Southern Society for Clinical Investigation American College of Physicians (Fellow) American Physiological Society European Respiratory Society Sigma Xi Undersea and Hyperbaric Medical Society The Society for Free Radical Biology and Medicine The Explorers Club (Fellow National 1998)
Board Certification: 1979 American Board of Internal Medicine (permanent)
Candidate number 071394 1982 A.B.I.M., Pulmonary Disease (permanent)
1988-1998 A.B.I.M., Critical Care Medicine
1998-2008 A.B.I.M., Critical Care Medicine
2010-2020 A.B.I.M., Critical Care Medicine Honors: 1983 Award for best research abstract supported by American Lung
Association of Florida 1985-1988 Elected Edward Livingston Trudeau Fellow
of the American Lung Association 1985-1988 Recipient of a Research Career Development Award from the VA
Research Service 1986 Elected Fellow of the American College of Physicians 1987-1992 FIRST Award, NIH NHLBI 1988 Elected to Southern Society for Clinical Investigation 1991-1992 Senior National Research Service Award, NIH NHLBI
5
1993-1998 Career Investigator Award, American Lung Association
1998 Elected Fellow (National) of the Explorers Club, New York, NY
2007 Sigma Xi 2009 ERS visiting professor, University of Giessen Lung Center
State Licensure: Florida, 1978; License No. 33585 Pennsylvania, 1981; License No. MD-025533-E Alabama, 1983; License No. 11035
Florida, 2004; License No. ME 89747 ACLS Provider Certification:
July 2010 – July 2012 DEA Number: AJ 2292427 National Provider Number: 1568410082 UPIN Number: C73518 Academic Activities:
1985-1994 Animal Care Subcommittee Birmingham VAMC
1985-2003 Graduate School Faculty Member, UAB
1985-1988 Member, Ph.D. committee for Don L. Stork, candidate in
respiratory physiology
1986-1991 Finance Subcommittee UAB Animal Resources Advisory Committee
6
1986-1989 Research Review Committee
American Heart Association Alabama Affiliate
1987-1992 Research Review Committee (national)
American Lung Association/American Thoracic Society 1987-1990 Trainer, Hypertension Research Program Training Grant
1991-2003 Mentor, M.D./Ph.D. program UAB
1992-2003 Mentor, academic internist program
UAB
1992-pres. Consulting physician Divers’ Alert Network Duke University, Durham, NC
1992-1995 Research Advisory Group (national)
VA Medical Research Service
1993 NIH-NIEHS Special Review Committee for RFA 92-04 Ozone: Mechanisms of Action
1994 Clinical Affairs Committee
Birmingham DVAMC
1994 Ad hoc Reviewer Small Business Phase I Grants NIH Special Review Committee
1994-2003 Budget Subcommittee
Research Service Birmingham VAMC
1994-1995 Chairman
VA Research Advisory Group (national) VA Medical Research Service
1995-2002 Pharmacy and Therapeutics Committee
Birmingham VAMC
1995-1996 Member, Ph.D. committee for Gang Yue, candidate in cellular physiology
7
1995 Ad hoc reviewer, USAMRDC
1996-2003 Scientist
Gregory Fleming James Cystic Fibrosis Center UAB
1996-2003 Member, Research and Development Committee
Birmingham VAMC
1997-2000 Member, Ph.D. committee for Stacie Probst, candidate in Physiology and Biophysics
2001-2004 Research Review Committee (national)
American Lung Association/American Thoracic Society
2002 Ad hoc member NIH NHLBI Lung Biology and Pathology Study Section
2003-2006 Member, Planning Committee, ATS RCMB Assembly
2004-pres. Member, Ph.D. committee for Maria Fernanda Pallin, candidate in Immunology
2006-pres. Reviewer, Explorers Club Grant Review Committee
2006-2007 UMMSM Department of Medicine research strategic planning
group (Dr. Robert Hoffman, chair) 2009 ERS visiting professor, University of Giessen Lung Center,
Giessen, Germany, 1 July 2009 – 14 July 2009 2011-pres. Chair, GRECC Advisory Committee
Board membership:
1996-pres. Member, Board of Directors Himalayan HealthCare, Inc. New York, NY (See http://www.himalayan-healthcare.org/)
2000-2005 President
Himalayan HealthCare, Inc. New York, NY
2004-pres. Chair, Board of Directors
8
South Florida VA Foundation for Research and Education (See http://SFVAFRE.org/)
Professional experience (miscellaneous):
1979-1981 ICU Physician and Coordinator of ICU Group Hollywood Memorial Hospital Hollywood, Florida
Oct. 12-31 National Oceanic and Atmospheric 1981 Administration Course in Diving Medicine
July 9-14 Cell Culture Course (preceptor U. Ryan) 1984 University of Miami
July 27- FASEB Summer Research Aug. 1 Conference on Lung Pharmacology 1986 Saxton River, Vermont
Aug.26-30 Critical Care Medicine Board 1987 Review Course
Houston, Texas
Jan. 24-30 Oxy-radicals in Molecular Biology 1988 and Pathology
UCLA Symposium, Park City, Utah
May 1-5 Conversational Molecular Biology 1989 Course
UAB Birmingham, Alabama
Jan. 29- Gordon Conference on “Oxygen Feb. 2 Radicals in Biology” 1990 Ventura, California
June 2-5 Aspen Lung Conference 1993 Aspen, Colorado
Apr. 14-May 2 Medical trek 1994 Tipling, Nepal
Apr. 18-May 1 Medical trek
1995 Tipling, Nepal
Jan. 8-12 Keystone Conference on "Oxidants from Molecules to Man"
9
1996 Santa Fe, NM
Jun. 15-24 NATO Advanced Study Institute on ARDS 1997 Corfu, Greece
Nov. 6-19 Medical trek 1997 Tipling, Nepal
Feb. 8-13 Gordon Conference on “Oxygen Radicals” 1998 Ventura, CA
May 16- 23 Co-director of course on “Physiology of special breathing gases in 1998 diving”
International Society of Aquatic Medicine Bonaire, Netherlands Antilles
June 2 - June 6 Aspen Lung Conference on “Acute Lung Injury” 1998
Mar. 18-Apr. 2 Medical trek 2000 Ilam (Mabu village), Nepal
June 2 - 6 Aspen Lung Conference on “Pulmonary Fibrosis” 2001 March 26- 28 ERS Conference on Acute Lung Injury 2004 Taormina, Italy
March 24- 27 ERS Conference on Hypoxia 2006 Taormina, Italy
Invited Presentations (selected):
Symposium on Extension of Oxygen Tolerance, University of Pennsylvania 26 May 1987
Symposium on Oxygen Toxicity, ACCP Meeting, Atlanta, Georgia 27 October 1987
Seminar on "Reoxygenation Lung Injury," University of Utah, Salt Lake City, Utah 9 November 1989
"Ischemia-Reperfusion Injury in the Lung," NIH NHLBI, Bethesda, Maryland 6 April 1990
RFA workshop on ischemia-reperfusion lung injury, NIH NHLBI, Bethesda,
10
Maryland 8 April 1991
Seminar on "Antioxidant defenses in acute lung injury," Fred Hutchinson Cancer Research Institute, Seattle, Washington 24 May 1991
Medical Grand Rounds "Clinical aspects of oxidant lung injuries," UAB, Birmingham, Alabama 6 June 1991
Respiratory physiology seminar, Dartmouth Medical School Hanover, NH 10 January 1992 Pulmonary research conference, UCSD School of Medicine San Diego, CA 5 April 1993
Chairman, "Antioxidant gene regulation following oxidant stress," ATS International Conference, San Francisco, CA 16 May 1993
Invited lecture on "Pulmonary oxygen toxicity," Experimental Biology '94 Anaheim, CA 14 April 1994
Invited lecture on "Hypoxic regulation of MnSOD activity," III Congreso Panamericano de Medicina Hyperbarica, Buenos Aires, Argentina 23 April 1996
Seminar on "Hypoxic regulation of MnSOD activity," Falcultad de Farmacia y Bioquimica Fisicoquimica, University of Buenos Aires, Buenos Aires, Argentina 25 April 1996
Medical grand rounds on “Regulation of lung SOD by hypoxia and oxidants,” Providence VAMC/Brown University, 27 February 1997
Pulmonary research seminar on “Regulation of lung SOD by hypoxia and oxidants,” University of Colorado, Denver, CO, 2 May 1997
"Divergent effects of hypoxia and oxidants on MnSOD expression," NATO Advanced Study Institute on ARDS Corfu, Greece, 18 June 1997
Research seminar on “Regulation of lung SOD by hypoxia and oxidants,” Webb-Waring Institute for Biomedical Research, Denver, CO, 16 September 1997
Invited research seminar on “MnSOD in hypoxia-reoxygenation of the alveolar epithelium,” Case-Western Reserve University, Cleveland, OH, 13 May 1999
Invited lecture on “Health and development in rural Nepal,” The Explorers Club, Atlanta, GA, 18 September 1999
11
Medical Grand Rounds "Idiopathic pulmonary fibrosis," UAB, Birmingham, Alabama 12 April 2000
Chairman, poster discussion “Regulation and role of NOS,” ATS meeting, Toronto, ON, 7 May 2000
Meet the Professor lecture on “Clinical implications of ROS and RNS in the lungs,” ATS meeting, Toronto, ON, 9 May 2000
Sunrise Seminar on “Respiratory physiology of diving,” ATS meeting, Toronto, ON, 10 May 2000 Consultants’ forum on idiopathic pulmonary fibrosis, InterMune, Inc., Dallas, TX 23 – 25 June 2000 Invited lecture on “Lung ischemia-reperfusion injury,” ERS-ATS meeting, Florence, IT, 3 September 2000 Medical Grand Rounds on “Protein nitration, reactive nitrogen species and function of lung allografts,” University of California at Irvine, 17 October 2000 Medical Grand Rounds on “Idiopathic pulmonary fibrosis,” Carraway Medical Center, Birmingham, AL, 11 November 2000 Cochair, “Poster Discussion: Mechanisms of acute and chronic lung injury,” ERS meeting, Berlin, Germany, 24 September 2001.
Discussant, Trans-Atlantic Airway Conference on “Oxidants and Antioxidants,” Lucerne, Switzerland 24, and 25 January 2002 Chair, “Redox signaling in lung cells,” ERS meeting, Vienna, Austria 29 September 2003 Lecture on “Mitochondrial reactive species and signaling in lung epithelial cells,” University of Miami mitochondrial interest group, 2 March 2004
Lecture on “H-R, redox signaling and antioxidant defense,” Pulmonary research conference, 19 January 2005
Discussant, ERS Conference on Hypoxia, Palermo, Italy 3 - 5 March 2005 Lecture on “Oxidant stress as a mechanism of exercise limitation in IPF,” Miami IPF Symposium, 22 April 2006 Organizer and scientific director, “Miami IPF Symposium,” Key Biscayne, FL 19-22 April 2006
Medical Grand Rounds on “Idiopathic pulmonary fibrosis,” University of Miami Miller
12
School of Medicine, November 21, 2007 Invited lecture on “Hypoxic regulation of cellular glutathione,” Helmholtz Zentrum, Munich, Germany, 3 July 2009 Lecture on “Hypoxic regulation of cellular glutathione,” Joint KliFo118/MBML graduate course, University of Giessen, Giessen, Germany, July 9, 2009 GRECC Grand Rounds on “Oxidant stress in IPF,” Miami VAHS, 13 January 2011 Rehabilitation Medicine Grand Rounds on “Scientific Basis of Pulmonary Rehabilitation,” University of Miami Miller School of Medicine, 24 January 2012
Ad Hoc Reviewer:
AJP: Cellular Physiology
AJP: Lung Cellular and Molecular Physiology
American Journal of Medicine
American Journal of Respiratory Cell and Molecular Biology
American Journal of Respiratory and Critical Care Medicine
American Journal of the Medical Sciences
American Review of Respiratory Disease
Chest
Free Radical Biology and Medicine
Hypertension
Journal of Applied Physiology
Journal of Cellular Physiology
Journal of Clinical Investigation
Lung
Pediatric Pulmonology
Proceedings of the Society for Experimental Biology and Medicine
13
Western Journal of Medicine
Editorial Board Membership: AJP: Lung Cellular and Molecular Physiology, 1989-1999 AJP: Cell Physiology, 1999-2002 Previous Trainees: Don L. Stork Ph.D. student in respiratory physiology 1985-1988 Supported by USAF Curtis F. Veal, M.D. Research fellow 1986-1988 Supported by AHA Clinician-Scientist Award Current position: Private practice, Seattle, WA Hongkui Jin, M.D. Post-doctoral fellow 1986-1990 Supported by NIH NHLBI training grant Current position: Scientist, Genentech Corp., San Francisco, CA Susan M. Harding, M.D. Research fellow 1986-1988 Supported by American Lung Association of Alabama Current position: Assistant professor of medicine, University of AL at Birmingham A. Lynne Brannen, M.D. Research fellow 1987-1989 Supported by American Lung Association Current position: Private practice, Augusta, GA William J. Russell, Ph.D. Post-doctoral fellow 1989-1994 Supported by VA Research Service Current position: Staff, LSU Shreveport John Jessup, M.D. Research fellow 1990-1992 Supported by American Lung Association Current position: Private practice, Melbourne, FL Thiagarajan Sambandam, Ph.D. Post-doctoral fellow 1991-1992
14
Supported by American Heart Association Current position: Research associate, University of AL at Birmingham Clifton R. Johnson, M.D. Post-doctoral fellow 1994-1996 Current position: Private practice, Little Rock, AR Gang Yue, M.D. Ph.D. student in physiology and biophysics 1995-1996 Supported by NIH NHLBI Current position: Research assistant professor, Emory University Stacey Probst Ph.D. student in physiology and biophysics 1997-2001 Supported by NIH NHLBI Joao de Andrade, M.D. Post-doctoral fellow 1998-2000 Current position: Instructor in Medicine, University of AL at Birmingham Charles S. Powell, Ph.D. Research associate 2001-2003 Supported by VA Merit Review Maria Pallen Masters degree student in immunology 2004-present Supported by University of Miami J. C. Rodriguez, M.D. Pulmonary research fellow 2005-2006 Supported by University of Miami Division of Pulmonary and Critical Care Medicine Ramiro Verdun, Ph.D. Assistant Professor of Medicine 2009-pres. Supported by the James and Esther King Foundation Qiongzhen Li, Ph.D. Post-doctoral fellow 2010-pres. Supported by the James and Esther King Foundation NIH Pathway to Independence application submitted. Clinical service and teaching:
Oct 1983 - Sept 1984 Months Pulmonary Inpatient 1 (1/84) University Consults 1 (3/84)
15
Critical Care Unit 1 (6/84) VA Consult/VA ICU 1 (8/84)
Total 4 Months
Oct 1984 - Sept 1985 Critical Care Unit 1 (12/84) Pulmonary Inpatient 1 (2/85) VA Consult 1 (5/85) General Medicine 1 (5/85) University Consults 1 (7/85) VA Consults 1 (8/85)
Total 6 Months
Oct 1985 - Sept 1986 Critical Care Unit 1 (10/85) General Medicine 1 (12/85) University/VA Consults 3 (2/86, 6/86, 8/86)
Total 5 Months Oct 1986 - Sept 1987
VA Consults 1 (3/87) General Medicine 1 (3/87) University Consults 1 (5/87) General Medicine 1 (7/87)
Total 4 Months Oct 1987 - Sept 1988 VA Consults/ICU 2 (10/87, 1/88) University Consults 1 (1/88) General Medicine 1 (7/88) PFL/Clinic/Bronchoscopy 1 (8/88)
Total 5 Months
Oct 1988 - Sept 1989 University Consults 1.5 (10/88, 2/89) PFL/Clinic/Bronchoscopy 1 (4/89) General Medicine 1 (7/89)
Total 3.5 Months Oct 1989 - Sept 1990
Pulmonary Inpatient 1 (08/90) University Consults 1 (10/89)
Total 2 Months
Oct 1990 - Sept 1991 Pulmonary Inpatient 1 (07/91)
University Consults 1 (03/91)
16
VA Consult/VA ICU 1 (10/90) Total 3 Months
Oct 1991 - Sept 1992 Pulmonary Inpatient 1 (08/92)
University Consults 1 (06/92) VA Consult/VA ICU 1 (05/92)
Total 3 Months Oct 1992 - Sept 1993
Critical Care Unit 1 (12/92) VA Consult/VA ICU 1 (11/92)
Total 2 Months
Oct 1993 - Sept 1994 Pulmonary Inpatient .2 (12/93)
VA Consult/VA ICU 2 (6/94, 8/94) Total 2.2 Months
Oct 1994 - Sept 1995 Pulmonary Inpatient 1 (10/94)
University Consults 1.1 (12/94 & 07/95) Critical Care Unit 1 (03/95)
Total 3.1 Months
Oct 1995 - Sept 1996 Pulmonary Inpatient 1 (07/96)
VA Consult/VA ICU 3 (12/95, 02/96, 09/96) Total 4 Months
Oct 1996 - Sept 1997 Pulmonary Inpatient 1 (07/97)
VA Consult/VA ICU 2 (12/96, 01/97) Total 3 Months
Oct 1997 - Sept 1998 3 (10/97, 08/98, 06/98) VA Consult/VA ICU Total 3 Months
Oct 1998 - Sept 1999 Pulmonary Inpatient 2 (11/98, 1/99)
VA Consult/VA ICU 1 (08/99) Total 3 Months
Oct 1999 - Sept 2000 Pulmonary Inpatient 2 (12/99, 4/00)
17
VA Consult/VA ICU 2.5 (8/99, 2/00, 7/00) Total 4.5 Months
Oct 2000 - Sept 2001 Pulmonary Inpatient 2 (12/00,74/01)
VA Consult/VA ICU 2 (2/01, 4/01) Total 4 Months
Oct 2001 - Sept 2002 Pulmonary Inpatient 2.5 (4/02; 8, 9/02)
VA Consult/VA ICU 2 (2/02; 6/02) Total 4.5 Months
Oct 2002 - Sept 2003 Pulmonary Inpatient 3 (4/03, 6/03, 9/03)
VA Consult/VA ICU 2 (2/01; 7/03) Total 5 Months
Oct 2003 – Sept 2004 1 (4/04) VA Consult Total 1 Month Oct 2004 – Sept 2005 1 (4/05) VA Consult Total 1 Month Oct 2005 – Sept 2006 1 (4/06) VA Consult Total 1 Month
Oct 2006 – Sept 2007 1 (4/07) VA Consult Total 1 Month
Oct 2007 – Sept 2008 1 (4/08) VA Consult Total 1 Month
Publications: Abstracts 1. Jackson, R. and L. Frank. Ozone and oxygen cross-tolerance: common
biochemical adaptations. Fed. Proc. 40(3): 739, 1981.
2. Jackson, R. and L. Frank. Ozone and oxygen cross-tolerance: interspecies comparison. Am. Rev. Resp. Dis.
3.
123(4): 215, 1981.
Jackson, R. Effect of endotoxin on rats in 2.0 and 4.0 ATA O2. Fed. Proc. 41(5):
18
1620, 1982.
4. Jackson, R. and J. Pisarello. Hypoxia preadaptation prevents oxygen-induced depression of lung angiotensin-converting enzyme activity. Am. Rev. Resp. Dis. 129(4 Part 2): A319, 1984.
5. Clark, J., Lambertsen, C., Pisarello, J., Jackson, R., and Gelfand, R.
Cardiopulmonary effects of continuous O2 exposure at 3.0 ATA for 3.5 hours in man. Undersea Biomed. Res. 11(1): 29, 1984.
6. Lambertsen, C., Clark, J., Gelfand, R., Jackson, R., et al. Tolerance of human
organs and functions to continuous hyperoxia. Undersea Biomed. Res. 11(1): 34, 1984.
7. Jackson, R.M., Harding, S.M., and Gensemer, P. Prostacyclin and thromboxane
production by endothelial monolayers in hyperoxia. Clin. Res. 33(2): 466A, 1985.
8. Chandler, D.B., Fulmer, J.D., and Jackson, R.M. Separation of rat alveolar
macrophage subpopulations by isopycnic centrifugation. Fed. Proc. 44(3): 533, 1985.
9. Jackson, R., Clark, J., Gelfand, R., Pisarello, J., Unger, M. and Lambertsen, C.
Effects of extreme hyperoxia (3.0 ATA O2 for 3.5 h) on human pulmonary function. Am. Rev. Resp. Dis. 131(4 Part 2): A184, 1985.
10. Narkates, A.J., Merrill, R., Jackson, R., and Oparil, S. Impaired conversion of
angiotensin I to angiotensin II in rats exposed to chronic hypoxia. Clin. Res. 33(2): 608A, 1985.
11. Gelfand, R., Clark, J.M., Lambertsen, C., Jackson, R., and Pisarello, J. Hyperoxia
at 3.0 ATA for 3.5 hours (in Predictive Studies V). Effects on ventilatory parameters. Undersea Biomed. Res. 12(1): 20, 1985.
12. Veal, C.F., Jackson, R.M., Brannen, A.L., Alexander, C.B. Bronchoalveolar
lavage in rabbits after re-expansion of collapsed lung. Clin. Res. 34(1): 203A, 1986.
13. Jackson, R., Veal, C., Alexander, C., Herrera, G., Brannen, A., Chandler, D.,
Fulmer, J. Re-expansion pulmonary edema: A proposed free radical mechanism. Am. Rev. Resp. Dis. 133(4): A275, 1986.
14. Veal, C.F., Jackson, R.M., Brannen, A.L., Alexander, C.B. Bronchoalveolar
lavage in rabbits after re-expansion of collapsed lung. Am. Rev. Resp. Dis. 133(4): A271, 1986.
19
15. Jackson, R., Chandler, D., Fulmer, J. Effects of leukotriene B4 on permeability and thromboxane and prostacyclin production of isolated perfused rat lungs. Am. Rev. Resp. Dis. 133(4): A283, 1986.
16. Pisarello, J., Flores, N.D., Jackson, R. Hypoxia preadaptation does not prevent
hyperoxic depression of prostaglandin E1 (PGE1) metabolism by rat lung. Am. Rev. Resp. Dis. 133(4): A106, 1986.
17. Oparil, S., Narkates, A.J., Jackson, R. Chronic hypoxia inhibits angiotensin-
converting enzyme in rat lung. Clin. Res. 34(1): 227A, 1986.
18. Oparil, S., Narkates, A.J., Jackson, R. Functional significance of converting enzyme inhibition by chronic hypoxia in the rat. Clin. Res. 34(1): 203A, 1986.
19. Chandler, D.B., Jackson, R.M., Fulmer, J.D. Normal rat interstitial macrophage
heterogeneity: Morphology, receptors, and phagocytosis. Am. Rev. Resp. Dis. 133(4): A95, 1986.
20. Oparil, S., Narkates, A., Jackson, R. Extrapulmonary angiotensin-converting
enzyme in rats exposed to chronic hypoxia. Circulation 74(4 Part 2):II-89, 1986.
21. Jackson, R., Veal, C., Alexander, C., Brannen, A., Fulmer, J. Neutrophils in re-expansion pulmonary edema. Clin. Res. 35(1): 29A, 1987.
22. Jackson, R., Veal, C., Alexander, C., Brannen, A., Fulmer, J. Neutrophils in re-
expansion pulmonary edema. Fed. Proc. 46(3): 995, 1987.
23. Brannen, A., Jackson, R., Veal, C., Fulmer, J. Alveolar macrophages and chemoattractant in collapsed lung. Am. Rev. Resp. Dis. 135(4): A502, 1987.
24. Jackson, R., Veal, C., Alexander, C., Brannen, A., Fulmer, J. Cellular and
biochemical mechanisms of re-expansion pulmonary edema. Am. Rev. Resp. Dis. 135(4): A188, 1987.
25. Jin, H., Yang, R., Chen, Y. -F., Jackson, R., Oparil, S. Infusion of arginine
vasopressin induces sustained reduction in pulmonary arterial pressure in hypoxia-adapted rats. Clin. Res. 35(3): 534A, 1987.
26. Jin, H., Yang, R., Chen, Y., Jackson, R., Oparil, S. Arginine vasopressin lowers
pulmonary artery pressure in hypoxic rats by a V1 receptor mediated mechanism. Chest 93(3): 184S, 1988.
27. Jin, H., Yang, R., Chen, Y. -F., Jackson, R., Oparil, S. Arginine vasopressin
produces sustained attenuation of pulmonary hypertension in hypoxia-adapted rats. Circulation 76(Suppl IV): IV-470, 1987.
20
28. Jackson, R., Brannen, A., Veal, C., Fulmer, J. Mitochondrial superoxide dismutase (MnSOD) and cytochrome oxidase (cyt ox) in collapsed lungs. The Physiologist 30(4): 239, 1987.
29. Jin, H., Yang, R., Chen, Y. -F., Jackson, R., Oparil, S. Pulmonary depressor
effect of arginine vasopressin in hypoxia-adapted rats is not mediated by soluble cyclic GMP or cyclooxygenase products. Clin. Res. 36(1): 44A, 1988.
30. Yang, R., Jin, H., Chen, Y. -F., Jackson, R., Oparil, S. Arginine vasopressin
lowers pulmonary arterial pressure in conscious rats adapted to chronic normobaric hypoxia. Clin. Res. 36(1): 44A, 1988.
31. Jin, H., Yang, R., Chen, Y. -F., Jackson, R., Oparil, S. Atrial natriuretic peptide
lowers pulmonary arterial pressure in conscious rats adapted to chronic normobaric hypoxia. Clin. Res. 36(1): 44A, 1988.
32. Jin, H., Yang, R., Jackson, R., Oparil, S. Arginine vasopressin induces
exaggerated release of atrial natriuretic peptide in conscious rats adapted to chronic hypoxia. Clin. Res. 36(1): 44A, 1988.
33. Jackson, R., Veal, C., Brannen, A. Evidence for free radical production in
homogenates of hypoxic/hypoperfused lungs. Clin. Res. 36(1): 26A, 1988.
34. Harding, S., Howard, T., Jackson, R. Cytoskeletal filamentous (F)-actin changes during exposure of endothelial cells to >95% O2. Clin. Res. 36(1): 26A, 1988.
35. Brannen, A., Veal, C., Jackson, R. Alveolar macrophage function in acute lung
injury. Clin. Res. 36(1): 26A, 1988.
36. Veal, C.F., Brannen, A.L., Jackson, R.M., Fulmer, J.D. Mechanism for neutrophil influx in re-expansion pulmonary edema. Clin. Res. 36(1): 27A, 1988.
37. Veal, C.F., Brannen, A.L., Jackson, R.M., Fulmer, J.D. Lodoxamide
tromethamine prevents neutrophil accumulation in re-expansion pulmonary edema. Am. Rev. Resp. Dis. 137(4 Part 2): 77, 1988.
38. Jin, H., Jackson, R., Yang, R., Chen, Y., Oparil, S. Exaggerated vasodilator effect
of atrial natriuretic peptide (ANP) in isolated perfused lungs from hypoxic rats. FASEB Journal 2(4): A722, 1988.
39. Yang, R., Jin, H., Chen, Y., Jackson, R., Oparil, S. V1 vasopressin receptor
agonist lowers pulmonary arterial pressure in conscious hypoxic rats. FASEB Journal
40. Jin, H., Yang, R., Chen, Y.,
. 2(4): 724, 1988.
Jackson, R., Oparil, S. Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats.
21
Clin. Res. 36(3): 625A, 1988.
41. Jin, H., Yang, R., Chen, Y., Jackson, R., Oparil, S. Chronic infusion of atrial natriuretic peptide attenuates the development of pulmonary hypertension in hypoxia adapted rats. Clin. Res. 37(1): 24A, 1989.
42. Veal, C., Jackson, R., Parks, D., Freeman, B. Allopurinol prevents neutrophil
accumulation in re-expansion pulmonary edema. Clin. Res. 37(1): 26A, 1989.
43. Veal, C., Harding, S., Jackson, R. Neutrophil chemoattractant release by oxygen-exposed endothelial cells. FASEB J. 3(3): A911, 1989.
44. Veal C.F., Kennedy, J.I., Jackson, R.M. Amiodarone exposure increases
endothelial cell injury by hyperoxia. Circulation 1989; 80(4):II-30.
45. Jin, H., Yang, R., Jackson, R., Oparil, S. Peptide agonist of the atrial natriuretic peptide clearance receptor lowers pulmonary artery pressure in hypoxia-adapted rats. Clin. Res. 37(2): 579A, 1989.
46. Jackson, R., McKellar, C., Veal, C. Effects of hypoxia (ischemia) and re-
oxygenation (reperfusion) on lung glutathione system. Am. Rev. Resp. Dis. 139(4 Part 2): A39, 1989.
47. Yang, R., Jin, H., Chen, Y., Jackson, R., Oparil, S. Cicletanine blunts the
pulmonary response to acute hypoxia in the rat. Clin. Res. 38(1): 35A, 1990.
48. Jin, H., Yang, R., Chen, Y., Jackson, R., Oparil, S. Atrial natriuretic peptide abolishes the pulmonary pressor response to acute hypoxia in the rat. Clin. Res. 38(1): 19A, 1990.
49. Jackson, R., Robison, T., McKellar, C., Veal, C., Forman, H. Alveolar neutrophils
and lavage fluid eicosanoids in re-oxygenation lung injury. Am. Rev. Resp. Dis. 141 (4 Part 2): A648, 1990.
50. Jackson, R., McKellar, C., Veal, C. Endogenous and exogenous catalase in lung
hypoxia/re-oxygenation injury. Am. Rev. Resp. Dis. 141 (4 Part 2): A162, 1990.
51. Yang, R.H., Jin, H., Chen, Y., Jackson, R., Nakao, K., Imura, H., Itoh, H., Mukoyarna, M., Oparil, S. Monoclonal antibody against atrial natriuretic peptide enhances pulmonary pressor response to hypoxia in rats. The American Society for Hypertension, 1990.
52. Russell, W.J., McKellar, C., Jackson, R. Purification and characterization of Mn-
containing superoxide dismutase isolated from rabbit liver. Clin. Res. 38(4): 928A, 1990.
22
53. Jessup, J., Jackson, R. Effects of cimetidine on lung permeability in re-expansion pulmonary edema. Clin. Res. 38(4): 958A, 1990.
54. Russell, W., McKellar, C., Jackson, R. Purification and characterization of Mn-
containing superoxide dismutase isolated from rabbit liver. Am. Rev. Resp. Dis. 143(4): A739, 1991.
55. Jackson, R., Russell, W. Hydrogen peroxide release by mitochondria from
normal and hypoxic lungs. Am. Rev. Resp. Dis. 145(4 Pt 2): 576, 1992.
56. Russell, W., Jackson, R. Mitochondrial superoxide dismutase (MnSOD) activity/protein content in hypoxic lung tissue. Am. Rev. Resp. Dis. 145(4 Pt 2): 577, 1992.
57. Russell, W., McKellar, C., Matalon, S., Jackson, R. Effects of severe hypoxia on
expression of MnSOD mRNA in alveolar epithelium. Am. Rev. Resp. Dis. 147(4 Part 2): A205, 1993.
58. Russell, W., McKellar, C., Jackson, R. Mitochondrial superoxide dismutase
protein expression in hypoxic/hypoperfused lung tissue. FASEB J. 7(4 Part I): A219, 1993.
59. Russell, W., Ho, Y-S., Jackson, R. Effects of hypoxia on lung MnSOD
expression. Clin. Res. 41(4): 807A, 1994.
60. Russell, W., Matalon, S., Jackson, R. MnSOD expression in alveolar epithelial cells from hypoxic and hypoperfused lungs. Clin. Res. 41(4): 807A, 1994.
61. Yue, G., Matalon, S., Jackson, R. Sodium (Na+) channel expression in rat lung
during adaptive and lethal hyperoxia. Clin. Res. 41(4): 738A, 1994.
62. Russell, W., Ho, Y-S., Jackson, R. Effects of hypoxia on lung MnSOD expression. Am Rev Resp Dis 149(4 Part 2): A460, 1994.
63. Russell, W., Matalon, S., Jackson, R. MnSOD expression in alveolar epithelial
cells from hypoxic and hypoperfused lungs. Am Rev Resp Dis 149(4 Part 2): A459, 1994.
64. Russell, W., Jackson, R. Expression of MnSOD in alveolar epithelial cells
cultured in hypoxia. Am Rev Resp Dis
65.
149(4 Part 2): A459, 1994.
Jackson, R., Yue, G., Russell, W., Benos, D., Matalon, S. Expression of epithelial sodium channel (a-rENaC) in normal and hyperoxic rat lung. FASEB J
8(5): A799, 1994.
66. Russell, J., Yue, G., Benos, D., Jackson, R., Olman, M., Matalon, S. Sublethal
23
hyperoxia increases expression of a-rENaC in alveolar type II (ATII) cells. FASEB J 9(4): A859, 1995.
67. Johnson, C., Myles, C., Matalon, S., Jackson, R. Na+-K+-ATPase mRNA
expression in rat lung during adaptive and lethal hyperoxia. J. Invest. Med. 44(1): 46A, 1996.
68. G. Parish, S. Helton, Y-S. Ho, S. Matalon, R. Jackson. Hypoxic regulation of
MnSOD mRNA and protein expression in alveolar type II (ATII) epithelial cells. Am. J. Resp. Crit. Care Med. 153(4 Part 2): A175, 1996.
69. C. Johnson, C. Myles, S. Matalon and R. Jackson. Na+-K+-ATPase subunit
mRNA expression in rat lung during adaptive and lethal hyperoxia. Am. J. Resp. Crit. Care Med. 153 (4 Part 2): A504, 1996.
70. R. Jackson, G. Parish, S. Helton. Modulation of MnSOD gene expression by
peroxynitrite. Free Radical Biology and Medicine, 1996.
71. S. Helton, G. Parish, R. Jackson. Hypoxia increases alveolar epithelial cell cytolysis induced by TNF-α. Am. J. Resp. Crit. Care Med. 155(4 Part 2): A191, 1997.
72. R. Jackson, G. Parish, S. Helton. Modulation of MnSOD gene expression by
peroxynitrite. Am. J. Resp. Crit. Care Med. 155(4 Part 2): A689, 1997.
73. G. Parish, E. Helton, R. Jackson. Hypoxia increases MnSOD gene promoter activity in lung epithelial cells. FASEB J 11(3): A646, 1997.
74. R. Jackson, T. Ohman, E. Helton, J. P. Crow, L. Viera, C.B. Alexander, S.
Matalon Epithelial lining fluid (ELF) and lung protein nitration in lung allotransplants. Free Radical Biology and Medicine 25(Suppl 1): S62, 1998.
75. R. Jackson, T. Ohman, E. Helton, J. P. Crow, L. Viera, C.B. Alexander, R.
Young, D. McGiffin, G. Zorn, J. deAndrade, J. Beckman, S. Matalon Protein nitration and chlorination in human lung allografts. Am. J. Resp. Crit. Care Med. 159(3): A272, 1999.
76. R. Jackson, G. Parish, E. Helton. Peroxynitrite modulates manganese-containing
superoxide dismutase gene expression in lung epithelial cells. Chest 116: 100S-101S, 1999.
77. Reactive nitrogen species in human lung allografts and clinical correlates J.
deAndrade, C.B. Alexander, R. Young, D. McGiffin, G. Zorn, J. Beckman, S. Matalon, S. Zhu, R. Jackson. Eur. Resp. J.
78. Chuanyu Li, Marcienne M. Wright and
14(Supp 30): 10S, 1999.
Robert M. Jackson. Reactive species
24
mediated lung epithelial cell death after hypoxia and reoxygenation. Am. J. Resp. Crit. Care Med.
79. JA deAndrade, KR Young, D McGiffin, G Zorn, CB Alexander, JD Christie,
161(3): A148, 2000.
R Jackson. Reactive nitrogen species correlate with airway inflammation in lung transplants. Am. J. Resp. Crit. Care Med.
161(3): A366, 2000.
80. J. A. de Andrade, J. D. Christie, C. B. Alexander, K. R. Young, R. M. Jackson. Reactive nitrogen species, myeloperoxidase and inflammation in lung transplants.
Eur. Resp. J
81. R. M. Jackson. Hypoxia and reoxygenation modulate lung epithelial cell glutathione content, oxygen consumption and reactive oxygen species (ROS) production.
. (16) Supp. 31: 374S, 2000.
Eur. Resp. J
., 2001.
82. Powell, C. and R. Jackson. Mitochondrial complex I and aconitase inactivation by hypoxia-reoxygenation: Modulation by mitochondrial MnSOD augmentation. Am. J. Resp. Crit. Care Med.
165(8): A57, 2002.
83. M. Wright, C. Myles and R. Jackson. Intratracheal “naked” DNA vaccination with pcDNA3-TNF-a, LPS-induced lung injury and mortality. Am. J. Resp. Crit. Care Med.
84. Increases in Plasminogen Activator Inhibitor-1 Predict Chronic Rejection in Lung
Transplant Recipients. K J Leon, S L Hallit, P Prabhakaran, R Jackson, J de Andrade, P O'Reilly, S Matalon, J Hickman-Davis and M A Olman.
165(8): A41, 2002.
Am. J. Resp. Crit. Care Med.
86. C. Powell, M. Wright, R. Jackson. p38mapk and MEK1/2 inhibition contribute to cellular reoxygenation injury. ERS Lung Science Conference, 2004.
165(8): A402, 2002. 85. Powell, C. Wright, M. and R. Jackson. MAPK and MEK inhibition contribute to
cellular reoxygenation injury. Experimental Biology, 2002.
87. R. Jackson, R. Garcia-Rojas. MAPK inhibition modulates Hsp27
phosphorylation and glutathione in lung epithelial cells. ERS Lung Science Conference, 2006.
88. J.C. Rodriguez, R. M. Jackson. Oxidant stress markers in IPF patients. Proc.
Am. Thorac. Soc.
89. R. Jackson, R. Garcia-Rojas. MAPK inhibition modulates Hsp27 phosphorylation and glutathione in lung epithelial cells.
, 2006.
Proc. Am. Thorac. Soc.
, 2006.
90. R. Jackson, R., Garcia-Rojas. Heat shock protein (Hsp27) expression regulates
25
glutathione and the response to oxidant stress in lung epithelial cells. Proc. Am. Thorac. Soc.
91. Gomez-Marin, O., C. Ramos, A. LaPerriere, R. Jackson. Vasodilator therapy of idiopathic pulmonary fibrosis (IPF): Design and initiation of a randomized controlled trial. European Respiratory Society, 2007.
175: A46, 2007.
92. Gomez-Marin, O., C. Ramos, M. Glassberg, R. Jackson. Serum and urine
isoprostanes as markers of oxidant stress after standardized exercise in patients with IPF. Am. J. Resp. Crit. Care Med
.177: A43, 2008.
93. Jackson R M, C F Ramos, M Glassberg, P Bejarano and O Gomez-Marin. Effects of sildenafil on exercise and dyspnea in IPF patients. Am. J. Resp. Crit. Care Med
., 2009.
94. Novela I, R M Jackson, C F Ramos and O Gomez-Marin. Baseline variables predicting change over six months in 6-minute walk test distance of IPF patients. Am. J. Resp. Crit. Care Med
., 2009.
95. Li Qiongzhen, Capellan D, Casamayor N, Maestre-Mesa J, Jackson R, Levitt R. IL-1 deficiency or over expression of IL-1 receptor antagonist protect against chronic tobacco smoke-induced lung injury in aged mice. Am. J. Resp. Crit. Care Med
., 2011.
96. Li Qiongzhen, Casamayor N, Maestre-Mesa J, Jackson R, Levitt R. IL1/IL1RA axis mediates bone marrow stem cell senescence and emphysema. ERS Lung Science Conference, 2011.
97. Li Qiongzhen, Jackson R, Capellan D, Van Snick J, Renauld J, Levitt R. The
Dutch hypothesis revisited: interleukin 9 over-expression promotes lung emphysema after chronic tobacco smoke exposure. ATS International Conference, 2012.
98. Jackson, R., C.F. Ramos, D. Cardenas, I. Gaunaurd, N. Eustis, M. Cohen, O.
Gomez-Marin. Effects of aerobic and strength training on symptoms and exercise capacity of IPF patients. ATS International Conference, 2012.
99. Gomez O, C.F. Ramos, D. Cardenas, I. Gaunaurd, N. Eustis, M. Cohen, R.M.
Jackson. Exercise training during pulmonary rehabilitation increases activity levels of IPF patients. ATS International Conference, 2012.
100. Gaunaurd IA, Gomez-Marin O, Ramos C, Cardenas D, Cahalin L, Cohen M, Jackson RM. Effects of a Pulmonary Rehabilitation Program on Exercise Capacity and Functional Mobility for Patients with IPF. ATS International Conference, 2012.
26
101. Daniel Pelaez, Robert M. Jackson, Qiongzhen Li, Roy Levitt, Herman S. Cheung. Derivation and characterization of young and aged stem cell populations in an interleukin-1 receptor antagonist mouse model system. European Respiratory Society, 2012.
101. Lawrence P. Cahalin, Carol F. Ramos, Constanza M. Sol, Meryl I. Cohen, Ignacio
A. Gaunaurd,, Diana D. Cardenas, Orlando W. Gómez-Marín, Robert M. Jackson. Exploratory Analysis of Ventilatory Inefficiency in Idiopathic Pulmonary Fibrosis A4164, ATS 2014
102. Robert M. Jackson, Carol F. Ramos, Constanza M. Sol, Meryl I. Cohen, Ignacio A.
Gaunaurd, Lawrence P. Cahalin, Orlando W. Gómez-Marín, Diana D. Cardenas . Exercise limitations and rehabilitation of IPF patients. A2639, ATS 2014
103. Gaunaurd I, Cohen M, Cardenas D, Cahalin L, Ramos C, Jackson R, Gómez-
Marín O. Health-related quality of life of IPF patients in a pulmonary rehabilitation program. A1800, ATS 2014
Original Papers
1. Jackson, R. and Frank, L. Ozone-induced tolerance to hyperoxia in rats. Am. Rev. Resp. Dis. 129(3): 425-429, 1984.
2. Jackson, R. and Pisarello, J. The endotoxin pretreated, oxygen-adapted rat model
hyperbaric hyperoxia. Aviat. Space Envir. Med. 55: 709-714, 1984.
3. Jackson, R. and Pisarello, J. Hypoxia preadaptation prevents oxygen-induced depression of lung angiotensin-converting enzyme activity. Am. Rev. Resp. Dis. 130: 424-428, 1984.
4. Jackson, R.M. Pulmonary oxygen toxicity. Chest 88(6): 900-905, 1985.
5. Chandler, D., Jackson, R., Briggs, A., Fuller, W., Fulmer, J. The effect of
bleomycin on lung metabolism of prostaglandin E2 in the hamster. Prostaglandins, Leukotrienes, and Medicine 19(2): 139-151, 1985.
6. Briggs, A., Chandler, D., Jackson, R., Fulmer, J. The effect of endotoxin on
bleomycin-induced lung fibrosis in the rat. Toxicol. Letters 27: 91-96, 1985.
7. Jackson, R.M., Narkates, A.J., and Oparil, S. Impaired conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia. J. Appl. Physiol.
8. Chandler, D.B., Fuller, W.C.,
60:(4): 1121-1127, 1986.
Jackson, R.M., Fulmer, J.D. Fractionation of rat
27
alveolar macrophages by isopycnic centrifugation: Morphological, cytochemical, biochemical, and functional properties. J. Leukocyte Biol. 39: 371-383, 1986.
9. Chandler, D.B., Fuller, W.C., Jackson, R.M., Fulmer, J.D. Studies of membrane
receptors and phagocytosis in subpopulations of rat alveolar macrophages. Am. Rev. Resp. Dis. 133: 461-467, 1986.
10. Buchalter, S., App, W., Jackson, L., Chandler, D., Jackson, R., Fulmer, J.D.
Bronchoalveolar lavage cell analysis in sarcoidosis: A comparison of lymphocyte counts and clinical course. Ann. N.Y. Acad. Sci. 465: 678-684, 1986.
11. Jackson, R.M., Chandler, D.B., Fulmer, J.D. Production of arachidonic acid
metabolites by endothelial cells in hyperoxia. J. Appl. Physiol. 61(2): 584-591, 1986.
12. Kennedy, J.I., Chandler, D.B., Jackson, R.M., Fulmer, J.D. Reduction in
bleomycin-induced lung hydroxyproline content by an iron-chelating agent. Chest 89(3 suppl.): 123S-125S, 1986.
14. Jackson, R.M., Veal, C.F., Alexander, C.B. and Fulmer, J.D. Re-expansion
pulmonary edema: A potential role for free radicals in its pathogenesis. Am. Rev. Resp. Dis. 137: 1165-1171, 1988.
15. Jackson, R.M., Ann, H.S. Effects of leukotriene B4 on permeability, prostacyclin
and thromboxane release by normal and oxygen pre-exposed isolated, perfused rat lungs. Prostaglandins, Leukotrienes and Essential Fatty Acids 32: 121-128, 1988.
16. Freeman, B.A., Jackson, R.M., Matalon, S., Harding, S.M. Biochemical and
functional aspects of oxygen-mediated injury to vascular endothelium. In Ryan, U.S., Ed. Endothelial Cells. Volume III. Boca Raton, CRC Press. 13-31, 1988.
17. Jackson, R.M., Veal, C.F., Alexander, C.B., Brannen, A.L., Fulmer, J.D.
Neutrophils in re-expansion pulmonary edema. J. Appl. Physiol. 65(1): 228-234, 1988.
18. Jackson, R.M., Ann, H.S., Oparil, S. MK351 uptake by isolated perfused rat
lungs after hypoxia adaptation and subsequent hyperoxia. Lung 166: 209-220, 1988.
19. Jin, H., Oparil, S., Ann, H., Yang, R., Jackson, R. Hypoxia-induced inhibition of
converting enzyme activity: Role in vascular regulation. J. Appl. Physiol. 63(3): 1012-1018, 1987.
20. Jin, H., Yang, R., Chen, Y.F., Jackson, R, Oparil, S. Arginine vasopressin lowers
arterial pressure in rats adapted to chronic hypoxia. Am. J. Med. Sci. 293(4): 274-278, 1987.
28
21. Oparil, S., Nakates, A., Jackson, R., Ann, H. Altered converting enzyme in lung
and extrapulmonary tissues of hypoxia adapted rats. J. Appl. Physiol. 65(1): 218-227, 1988.
22. Jackson, R.M., Brannen, A., Veal, C.F., Fulmer, J. Superoxide dismutase and
cytochrome oxidase in collapsed lungs: Possible role in re-expansion edema. J. Appl. Physiol 65(1): 235-241, 1988.
23. Shin, M.S., Jackson, R.M., Kang-Jey, H. Tracheobronchomegaly (Mounier-Kuhn
Syndrome): CT diagnosis. Am. J. Roentgenology 150: 777-779, 1988.
24. Jin, H., Yang, R.H., Thornton, R., Chen, Y.-F., Jackson, R., Oparil, S. Atrial natriuretic peptide lowers pulmonary arterial pressure in rats adapted to chronic hypoxia. J. Appl. Physiol. 65(4): 1729-1735, 1988.
25. Jin, H., Yang, R., Chen, Y.-F., Jackson, R., Oparil, S. Chronic infusion of atrial
natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats. Trans. of the American Assoc. of Physicians CI: 185-192, 1988.
26. Jackson, R.M., Ann, H., Oparil, S. Hypoxia-induced oxygen tolerance:
Maintenance of endothelial function. Exp . Lung. Res. 15: 23-32, 1988.
27. Jin, H., Yang, R., Chen, Y.-F., Thornton, R.M., Jackson, R.M., Oparil, S. Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. J. Applied Physiol. 66(1): 151-106, 1989.
28. Jin, H., Chen, Y.-F., Yang, R., McKenna, T., Jackson, R., Oparil, S. Arginine
vasopressin lowers pulmonary arterial pressure in rats adapted to chronic hypoxia by releasing atrial natriuretic peptide. Am. J. Med. Sci. 298(4): 227-236, 1989.
29. Veal, C., Jackson, R., Brannen, A., Fulmer, J. Lodoxamide tromethamine
prevents neutrophil accumulation in re-expansion pulmonary edema. J. Cardiovasc. Pharmacol. 14(2): 227-232, 1989.
30. Jackson, R., Veal. C. Re-expansion, re-oxygenation and rethinking. Am. J. Med.
Sci. 298(1): 44-50, 1989.
31. Jin, H., Yang, R-H., Chen, Y-F., Jackson, R., Oparil, S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J. Clin. Invest. 85(1): 115-120, 1990.
32. Jin, H., Chen, Y., Yang, R., Jackson, R., Oparil, S. Atrial natriuretic peptide
clearance receptor agonist lowers pulmonary arterial pressure in hypoxic rats. J. Appl. Physiol. 68(6): 2413-2418, 1990.
29
33. Jackson, R., Veal, C. Effects of hypoxia and re-oxygenation on lung glutathione system. AJP 259: (Heart and Circ. Physiol. 28): H518-H524, 1990.
34. Jackson, R., Veal, C., Beckman, J., Brannen, A. Polyethylene glycol-conjugated
superoxide dismutase in unilateral lung injury due to re-expansion (re-oxygenation). Am. J. Med. Sci. 300(1): 22-28, 1990.
35. Jin, H., Yang, R., Chen, Y., Jackson, R., Itoh, H., Mukoyama, M., Nakao, K.,
Imura, H., Oparil, S. Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. J. Appl. Physiol. 71(3): 807-814, 1991.
36. Clark, J., Jackson, R., Lambertsen, C., Gelfand, R., Hiller, D., Unger, M.
Pulmonary function in man after oxygen breathing at 3.0 ATA for 3.5 hours. J. Appl. Physiol. 71(3): 878-885, 1991.
37. Jackson, R., Russell, W., Veal, C. Endogenous and exogenous catalase in re-
oxygenation lung injury. J. Appl. Physiol. 72(3): 858-864, 1992.
38. Russell, W., Jackson, R. MnSOD protein content changes in hypoxic/hypoperfused lung tissue. Am J Resp Cell Molec Biol 9(12): 610-616, 1993.
39. Russell, W., Jackson, R. Hydrogen peroxide release by mitochondria from
normal and hypoxic/hypoperfused lungs. Am J Med Sci 308(4): 239-243, 1994.
40. Russell, W., Matalon, S., Jackson, R. MnSOD expression in alveolar epithelial cells from hypoxic and hypoperfused lungs. Am J Resp Cell Molec Biol 11: 366-371, 1994.
41. Russell, W., Parish G., Ho, Y-S., Jackson, R. Effects of hypoxia on lung MnSOD
expression. Am. J. Physiol. (Lung Cell. and Molec. Physiol.) 13(2): L221-L226, 1995.
42. Yue, G., Russell, W., Benos, D., Jackson, R., Olman, M., Matalon, S.
(communicated by John A. Clements, M.D.) Increased expression and activity of sodium channels in alveolar type II cells of hyperoxic rats. PNAS USA 92(18): 8414-8418, 1995.
43. Matalon, S., Benos, D., Jackson, R. Biophysical and molecular properties of
amiloride-inhibitable Na+ channels in alveolar epithelial cells. Am. J. Physiol. 271 (Lung Cell. and Molec. Physiol. 15): L1-L22, 1996.
44. Jackson, R., Parish, G., Ho, Y-S. Effects of hypoxia on expression of superoxide
dismutases in cultured ATII cells and lung fibroblasts. Am. J. Physiol. 271 (Lung Cell. and Molec. Physiol. 15): L955-L962, 1996.
30
45. Pisarello, J., Flores, D., Jackson, R. Effects of hypoxia and hyperoxia on lung prostaglandin E1 metabolism. Am. J. Med. Sci. 313(3): 147-152, 1997.
46. Johnson, C., Guo, Y., Helton, S., Matalon, S., Jackson, R. Modulation of lung
and alveolar epithelial Na+, K+-ATPase gene expression by hyperoxia. Exp. Lung Res. 24: 173-188, 1998.
47. R. Jackson, G. Parish, E. Helton. Peroxynitrite modulates MnSOD gene
expression in lung epithelial cells. Free Radical Biology and Medicine 25(4/5): 463-472, 1998.
48. T. Ohman, G. Parish, Y-S. Ho, R. Jackson. Hypoxic modulation of MnSOD
promoter activity and gene expression in lung epithelial cells. Am J Resp Cell Molec Biolhttp://ajrcmb.atsjournals.org/cgi/reprint/21/1/119.pdf
21: 119-127, 1999.
49. Jackson, R., E. Helton, L. Viera, T. Ohman. Survival, lung injury and lung
protein nitration in heterozygous MnSOD knockout mice in hyperoxia. Exp. Lung Res. 25(7): 631-646, 1999.
50. deAndrade, J., J. Crow, L. Viera, C. B. Alexander, K. R. Young, D. C. McGiffin,
G. Zorn, S. Matalon, R. Jackson. Protein nitration, metabolites of reactive nitrogen species and inflammation in lung allografts. Am. J. Resp. Crit Care Med.http://ajrccm.atsjournals.org/cgi/content/full/161/6/2035
161: 2035-2042, 2000.
51. Jackson, R. The basics of diving-related respiratory problems. J. Resp. Dis
http://www.findarticles.com/cf_0/m0BSO/10_21/66931637/p1/article.jhtml?term=%22Robert+M+Jackson%22
. 21(10): 613-618, 2000.
52. de Andrade, J., C. B. Alexander , L. Viera, K. R. Young, D. C. McGiffin, G. Zorn, R. Jackson. Reactive nitrogen species and myeloperoxidase correlate with airway inflammation in lung transplant patients. J. Invest. Med
http://journals.bcdecker.com/pubs/JIM/volume%2049,%202001/issue%2002,%20March/JIM_2001_34043/JIM_2001_34043.pdf
49(2): 166-172 2001.
53. Li, C., M. Wright and R. Jackson. Reactive species mediated injury of human
lung epithelial cells after hypoxia-reoxygenation. Exp. Lung Res.
http://taylorandfrancis.metapress.com/media/B5CR1PYHYP2K9ELLMV56/Contributions/U/F/E/V/UFEVC2E5TA9YBA79.pdf
38(5): 373-389, 2002.
54. Li, C. and R. Jackson. Cellular and molecular mechanisms of reoxygenation injury. Am. J. Physiol. (Cell Physiol.)282: C227-C241, 2002.
31
http://ajpcell.physiology.org/cgi/content/full/282/2/C227
55. Powell, C. Wright, M. and R. Jackson. Mitochondrial Complex I and aconitase during hypoxia-reoxygenation: Modulation of enzyme activities by mitochondrial MnSOD augmentation. Am. J. Physiol. (Lung Cell. and Molec. Physiol.
) 285: L189-L198, 2003. http://ajplung.physiology.org/cgi/content/full/285/1/L189
56. Baldus S., Jason P. Eiserich, Robert M. Jackson, Bruce Alexander, Bruce A.
Freeman. Spatial mapping of nitrotyrosine in vascular and pulmonary inflammatory diseases reveals a pivotal role for myeloperoxidase as a catalyst for tyrosine nitration in vivo. Free Radical Biol. Med.http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T38-46G4C98-5-F&_cdi=4940&_user=687830&_orig=browse&_coverDate=10%2F01%2F2002&_sk=999669992&view=c&wchp=dGLbVzb-zSkWW&md5=279b21655d2ca9ceb8307dcc294be02c&ie=/sdarticle.pdf
33 (7): 1010-1019, 2002.
57. Wright, M., C. Powell and R. Jackson. Intratracheal tumor necrosis factor alpha-expressing plasmid vector decreases LPS lethality in mice. Exp. Lung Research
http://taylorandfrancis.metapress.com/media/N2V6E330986RNNAB1PFM/Contributions/U/F/E/V/UFEVC2E5TA9YBA79.pdf
30: 653-671, 2004.
58. Powell, C., M. Wright and R. Jackson. p38mapk and MEK1/2 inhibition contribute to cellular oxidant injury after hypoxia. Am J Physiol (Lung Cell Molec Physiol
) 286: L826-L833, 2004. http://ajplung.physiology.org/cgi/reprint/00119.2003v1.pdf
59. Shah, N., P. Noble, R. Jackson, T. King, S. Nathan, M. Padilla, G. Raghu, M. Rhodes, M. Schwarz, G. Tino and R. Dubois. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 22: 167-174, 2005. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16315778&query_hl=5&itool=pubmed_docsum
60. Jackson, R. and R. Garcia-Rojas. Kinase activity, Hsp27 phosphorylation and lung epithelial cell glutathione. Exp. Lung Research 34(5): 245-262, 2008. http://www.informaworld.com/smpp/content~content=a792973715~db=all~order=page
61. Jackson, R. and C. Fell. Etanercept for idiopathic pulmonary fibrosis: Lessons on clinical trial design. Am. J. Resp. Crit. Care Med. 178: 889-893, 2008. http://ajrccm.atsjournals.org/cgi/reprint/178/9/889-a?maxtoshow=&HITS=&hits=&RESULTFORMAT=&andorexacttitle=and&andorexacttitleabs=and&fulltext=IPF&andorexactfulltext=and&searchid=1&usestrict
32
dates=yes&resourcetype=HWCIT&ct
62. Jackson, R. and Gupta, C. Hypoxia and kinase activity regulate lung epithelial cellular glutathione. Exp Lung Research
36: 1-12, 2010.
http://informahealthcare.com/doi/pdf/10.3109/01902140903061795 63. Jackson, R., C. Ramos, M. Glassberg, P. Bejarano, O. Gomez-Marin. Sildenafil
therapy and exercise tolerance in idiopathic pulmonary fibrosis: a randomized, controlled trial. Lung
188: 115-123, 2010.
http://www.springerlink.com/content/t126x778137w8t6g/fulltext.pdf 64. Jackson, R., C. Ramos, C. Gupta, O. Gomez-Marin. Exercise decreases plasma
antioxidant capacity and increases urinary isoprostanes in IPF. Respiratory Medicine 104: 1919-1928, 2010. http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WWS-50VGHFS-1-C&_cdi=7138&_user=687830&_pii=S0954611110003422&_origin=gateway&_coverDate=12%2F31%2F2010&_sk=998959987&view=c&wchp=dGLbVzb-zSkzV&md5=62f39c32eeb3039bbaa538eaca09e6d1&ie=/sdarticle.pdf
65. Jackson, R. and Gomez-Marin, O. Development and utility of pirfenidone in the
treatment of idiopathic pulmonary fibrosis: Review of preclinical science and recent clinical trials. Transplant Research and Risk Management 2011:3 55–63.
66. Qiongzhen, L., Jackson, R., Pham, S., Levitt, R. Critical role of IL1 receptor
antagonist in aging-induced emphysema. Submitted, 2012. 67. Roy, D., Okoh, V., Garba, N., Penny, R., Das, J., Deoraj, J., Singh, P., Sarkar,
Felty, Q., Jackson, R. Redox signaling to nuclear regulatory proteins by reactive oxygen species contributes to estrogen-induced breast tumor development. Submitted, 2013.
68. Jackson, R. Ramos, C., Sol, C., Cohen, M., Gaunaurd, I., Cahalin, L., Gómez-
Marín, O., Cardenas, D. Exercise limitation in IPF patients: A randomized trial of pulmonary rehabilitation. In press, Lung 2014 (DOI 10.1007/s00408-014-9566-9).
69. Gaunaurd, I., Gómez-Marín, O., Ramos, C., Sol, C., Cohen, M., Cahalin, L.,
Jackson, R. Physical activity and quality of life improvements of patients with IPF completing a pulmonary rehabilitation program. In press, Respiratory Care
70. Cahalin, Lawrence P., Arena, Ross, Cohen, Meryl I., Gaunaurd, Ignacio A., Eustis, Nicole, Ramos, Carol F., Sol, Constanza M., Cardenas, Diana D, Gómez-Marín, Orlando W.,
2014.
Jackson, Robert M. Physiologic mechanisms of maximal and submaximal exercise limitation in idiopathic pulmonary fibrosis. Submitted,
33
2014. Book Chapters and Symposium Proceedings
1. Jackson, R. The endotoxin-pretreated, 1.0 ATA O2-adapted rat model in 2.0 and 4.0 ATA O2. In Underwater Physiology VIII: Proc. Eighth Symp. on Underwater Physiol.
Ed. A.J. Bachrach, Bethesda, Maryland: Undersea Med. Soc., 1984 (51-54).
2. Jackson, R., Veal, C., Fulmer, J., Alexander, C. Re-expansion pulmonary edema: A proposed free radical mechanism. In Bove A, Bachrach A, Greenbaum L, Eds. Underwater and Hyperbaric Physiology IX
. Bethesda: Undersea Med. Soc., 1987; 643-656.
3. Jackson, R.M. Pulmonary Oxygen Toxicity: A Contemporary Survey of Basic and Clinical Aspects. In Hollinger M.A., Ed. Current Topics in Pulmonary Pharmacology and Toxicology
. Volume 3. Philadelphia: Praeger Publishing Co. 27-52, 1987.
4. Yang, R., Jin, H., Chen, Y.-F., Jackson, R., Oparil, S. Atrial natriuretic peptide prevents hypoxia-induced pulmonary hypertension in rats. Am. Society of Hypertension Series. Progress in atrial peptide research
. Laragh J., Brenner, B. (eds). Raven Press, New York, p529-533, 1989.
5. Jackson, R.M. Oxygen-induced lung injury: Molecular, pharmacologic, and therapeutic aspects. Clin. Chest Med.
11(1): 73-86, 1990.
6. Jackson, R. "Oxygen therapy and toxicity" in Ayres, S., Grenvik, A., Holbrook, P., Eds. Textbook of Critical Care
3d edition. W.B. Saunders Co., 1995, pp 784-789.
7. Duvall M, Guo Y, Jackson R,
Matalon S. Regulation of sodium transport across the alveolar epithelium by hyperoxia. In: Oxygen, Gene Expression and Cellular Function. Clerch, L. and Massaro, D., Eds. New York, Marcel Dekker, 1997, pp 339-366.
8. Jackson, R. Oxygen as a pharmaco-therapeutic agent in the critically ill. In: Oxford Textbook of Critical Care
. Webb. A., Shapiro M., Singer, M., Suter, P., Eds. Oxford, Oxford University Press, 1998, pp 1265-1269.
9. Jackson, G. Parish, E. Helton. "Divergent effects of hypoxia and oxidants on MnSOD expression," In: Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management. S. Matalon and I. Sznajder, Eds. New York and London, Plenum Publishing Corp. NATO ASI Series A: Life Sciences
Miscellaneous Publications
Vol. 297: 225-233, 1998.
34
1. Jackson, R., Orland, M. Parathyroid adenoma in a patient with multiple myeloma.
South. Med. J. 72(10): 1336-1337, 1979.
2. Jackson, R. Re: Acute oxygen toxicity in a saturation diver working in the North Sea [letter]. Undersea Biomed. Res. 10(3): 265-266, 1983.
3. Garcia, J., Jackson, R., Myers, J., Hickey, N., Campbell, M. Medical pathology
conference. Persistent pneumonia in a 40-year old diabetic. Ala. J. Med. Sci. 23(2): 184-188, 1986.
4. Jackson, R. Book review. Practical fiberoptic bronchoscopy. Ala. J. Med. Sci.
23(1): 104, 1986.
5. Jackson, R. Zen and the art of brain maintenance [letter]. Crit. Care Med. 17(8): 843, 1989.
6. Jackson, R. Medicine in Shangri-La. AMAA Quarterly
http://www.himalayan-healthcare.org/medinshang.pdf 9(3): 12-13, 1995.
7. Jackson, R. Practicing medicine in Shangri-La. Wilderness Medicine Newsletter 11(1): 1, 6-7, 13, 1995 (winter).
8. Jackson, R. “Essentials of underwater photography.” Best Publishing Company,
Flagstaff, AZ. 2000. (ISBN 0-941332-77-2; Library of Congress Catalog Number 99-61589)
9. Jackson, R. Book review. The ECHM Collection, Volume 1: Consensus conferences and workshops, 1994-1999. Respiratory Care 51(1): 6, 2006.
Grant Support (Annual Direct Costs): Principal Investigator
1984-1985 American Lung Association Research Grant ($13,580)
1984-1985 VA Research Advisory Group Funding
($25,000)
1985-1988 E.L. Trudeau Scholar Fellowship ($25,000/yr)
1985-1988 VA Research Service Merit Review (30% effort)
"Lung Endothelial Cells in Oxygen-Induced Injury" ($78,324/3 yr)
35
1985-1988 VA Research Career Development Award
($72,000/yr)
1986-1988 ALA Research Fellowship (National, A. Brannen) ($35,000/2 yr)
1987-1989 American Heart Association AL Affiliate (30% effort)
"Basic mechanisms of re-expansion pulmonary edema" ($40,000/2 year)
1987-1992 NIH NHLBI 1 R29 39147 (50% effort)
"Basic mechanisms of re-expansion pulmonary edema" ($284,931/5 yr)
1988-1993 VA Research Service Merit Review (30% effort)
"Lung cell hypoxia and oxidant stress: Mechanistic relationships" ($387,850/5 yr)
1989-1991 American Heart Association Alabama Affiliate
(20% effort) "Intracellular free radical sources in re-oxygenated lungs" ($50,000/2 yr)
1989-1992 Council for Tobacco Research - USA, Inc.
(10% effort [S. Oparil is principal investigator]) "Atrial natriuretic peptide in the pathogenesis of hypoxic pulmonary hypertension" ($240,000/3 yr)
1989-1991 ALA Research Fellowship (National, J. Jessup) ($35,000/2 yr)
1991-pres General clinical research center protocol 508
"Therapeutic action of atrial natriuretic peptide in patients with hypoxic pulmonary hypertension" ($5000/yr)
1991-1994 American Heart Association 91006150
"Intracellular free radical sources in ischemia reperfusion lung injury" ($40,000/yr)
1991-1992 NIH NHLBI F33 HL08483
"Regulation of MnSOD in Mammalian Lung" ($35,300/yr)
36
1993-1998 American Lung Association Career Investigator Award
"Lung cell hypoxia and oxidant stress" ($175,000/5 yr)
1994-1997 VA Research Service Merit Review
"Lung cell hypoxia and oxidant stress" ($315,700/3 yr)
1994-1997 NIH NHLBI HL 31197
(10% effort) "Pathophysiology of sublethal oxygen in injured lungs" ($721,580/5 yr)
1997-2000 ONR
(20% effort [S. Matalon is principal investigator]) "Gene transfer to normal and injured epithelium: Implications in the treatment of ARDS" ($816,9923 yr)
1997-2000 NIH NHLBI HL 57801
(50% effort) "Lung cellular hypoxia and oxidant stress" ($673,992/3 yr)
1998-2002 VA Research Service Merit Review
(30% effort) "Hypoxic regulation of SOD’s in acute lung injuries" ($422,400/4 yr)
2000-2001 InterMune Pharmaceuticals, Inc. “A phase II/III study of the safety and efficacy of subcutaneous recombinant ACTIMMUNE (interferon-γ 1b, rINF-γ 1b) in patients with idiopathic pulmonary fibrosis (IPF)” ($123,310/yr)
2001-2002 NIH NHLBI DK-97-010 (7.5% effort) "Intratracheal ‘naked’ plasmid DNA and lung inflammation" ($100,000/2 yr)
2001-2004 UAB-HSF General Endowment Fund (effort not specified) “UAB-HSF IPF Clinic” ($120, 000/3 yr)
37
2001-2003 AHA Grant-in-Aid (40% effort) "Reactive species and lung epithelial reoxygenation injury" ($120,000/2 yr)
2003-2005 AHA Grant-in-Aid (40% effort) "Reactive species and lung epithelial reoxygenation injury" ($140,000/2 yr)
2003-2004 Actelion, Inc. “Bosentan use in interstitial lung disease (BUILD)” ($140,000)
2005-2006 InterMune, Inc. “IPF symposium” unrestricted educational grant ($40,000)
2006-2009 VA Merit Review (25% effort) “Vasodilator therapy and exercise tolerance in IPF patients” ($282,700/3 yr)
2009-2013 VA Merit Review (submitted 6/15/09) (25% effort) “Pulmonary rehabilitation of IPF patients: Effects of exercise and oxidant stress” ($721,856/4 yr)
2009-2010 Novartis Pharmaceuticals Corporation contract USCDMA425 (effort not specified) “A randomized, double-blind, controlled study to compare indacaterol with open label tiotropium versus open label tiotropium in COPD” ($97,838)
2010-2013 VA Merit Review 1 I01 RX000265-01 (25% effort) “Rehabilitation of IPF patients: Effects of exercise and oxidant stress” ($807,433)